Mutational hotspots indicate selective pressure across a population of tumor samples, but their prevalence within and across cancer types is incompletely characterized. An approach to detect significantly mutated residues, rather than methods that identify recurrently mutated genes, may uncover new biologically and therapeutically relevant driver mutations. Here, we developed a statistical algorithm to identify recurrently mutated residues in tumor samples. We applied the algorithm to 11,119 human tumors, spanning 41 cancer types, and identified 470 somatic substitution hotspots in 275 genes. We find that half of all human tumors possess one or more mutational hotspots with widespread lineage-, position-and mutant allele-specific differences, many of which are likely functional. In total, 243 hotspots were novel and appeared to affect a broad spectrum of molecular function, including hotspots at paralogous residues of Ras-related small GTPases RAC1 and RRAS2. Redefining hotspots at mutant amino acid resolution will help elucidate the allele-specific differences in their function and could have important therapeutic implications.
A n A ly s i s
Mutational hotspots indicate selective pressure across a population of tumor samples, but their prevalence within and across cancer types is incompletely characterized. An approach to detect significantly mutated residues, rather than methods that identify recurrently mutated genes, may uncover new biologically and therapeutically relevant driver mutations. Here, we developed a statistical algorithm to identify recurrently mutated residues in tumor samples. We applied the algorithm to 11,119 human tumors, spanning 41 cancer types, and identified 470 somatic substitution hotspots in 275 genes. We find that half of all human tumors possess one or more mutational hotspots with widespread lineage-, position-and mutant allele-specific differences, many of which are likely functional. In total, 243 hotspots were novel and appeared to affect a broad spectrum of molecular function, including hotspots at paralogous residues of Ras-related small GTPases RAC1 and RRAS2. Redefining hotspots at mutant amino acid resolution will help elucidate the allele-specific differences in their function and could have important therapeutic implications.
Among the best-studied therapeutic targets in human cancers are proteins encoded by genes with tumor-specific mutational hotspots, such as KRAS, NRAS, BRAF, KIT and EGFR. The acquisition of somatic mutations is one of the major mechanisms responsible for the dysregulation of proliferation, invasion and apoptosis, which is required for oncogenesis. Comprehensive genomic characterization of tumors has produced valuable insights into the somatic aberrations that define individual cancer types 1,2 , broadening our understanding of the dysfunctional molecular pathways that govern tumor initiation, progression and maintenance. These data have spurred the development of computational algorithms to identify cancer driver genes, defined as those in which molecular abnormalities lead to a fitness advantage for the affected cancer cells.
These computational approaches develop either gene-level statistical models that exploit different mutational patterns [3] [4] [5] [6] to identify significantly mutated genes or use weight-of-evidence-based methods 1, 7 that are heuristic and ratiometric in approach. Together, these methods focus on identifying cancer genes from a multitude of diverse molecular abnormalities affecting the gene. However, not all genomic alterations in cancer genes are driver alterations. Furthermore, not all driver alterations in a cancer gene have the same functional impact, and are therefore likely to have varying clinical meaning. The potentially diverse functional effects of different lesions in the same gene are not captured and reported by gene-level models, but are rather assumed to be equivalent. However, emerging data indicate that different hotspot mutations in the same cancer gene can be functionally distinct in vitro and in vivo and display different clinical phenotypes and drug sensitivity [8] [9] [10] [11] . Moreover, it is unknown how widespread such hotspot-specific functional differences may be.
To date, studies of hotspot mutations in cancer have been limited to within individual tumor types [12] [13] [14] or have focused on individual cancer genes across tumor types 15 . A systematic population-scale, cross-cancer, genome-wide analysis of mutational hotspots has not been performed and the extent to which mutant allele-and lineagespecific effects exist remains unknown. As broad-based clinical sequencing has begun to inform the care of individual cancer patients, this would begin to address one of the greatest challenges in the practice of genomically driven cancer medicine: interpreting the biological and clinical importance of mutations in even presumed actionable cancer genes as they arise in oncology clinics.
To address this challenge, we develop a computational algorithm to identify driver mutations, rather than driver genes. We assembled and rigorously curated a large repository of cancer genome data consisting of the sequenced tumor exomes and whole genomes of 11,119 human tumors representing 41 tumor types. We developed a biologically aware, statistically principled computational model by combining observed biological phenomena such as nucleotide mutability and varying gene-specific mutation rates into coefficients identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity A n A ly s i s that we incorporate into binomial statistics. From this, we systematically identify individual recurrent mutations and associate these with related temporal and transcriptional data to investigate lineagespecific variation in mutations, and identify novel hotspots with likely clinical implications.
RESULTS

Landscape of hotspot mutations in primary human cancer
We collected the mutational data from the sequenced exomes and genomes of 11,119 human tumors in 41 tumor types (Supplementary Table 1 ). These originate from diverse sources including large international consortia and various published studies. This cohort represents a broad range of primary human malignancies with three or more tumor types in each of nine major organ systems (Fig. 1a) . The repository consists of 2,007,694 somatic substitutions in proteincoding regions with a median of 57 mutations (25 and 125 mutations; 25th and 75th percentile, respectively) per tumor-normal pair with significant variability in mutation rates among and between tumors and types 4, 16 . In total, 19,223 human genes harbor at least one somatic mutation in this data set.
Here, we define a mutational hotspot as an amino acid position in a protein-coding gene that is mutated (by substitutions) more frequently than would be expected in the absence of selection. In this analysis, we focus exclusively on individual substitutions rather than other somatic abnormalities such as translocations, amplifications, deletions or epigenetic modifications. To identify mutational hotspots, including low-incidence mutations, we developed a binomial statistical model that incorporates several aspects of underlying mutational processes including nucleotide context mutability, gene-specific mutation rates and major expected patterns of hotspot mutation emergence ( Supplementary Figs. 1a and 2 , Supplementary Code and Online Methods). As considerable variability exists in the methods and standards for mutation calling used by individual studies and centers, we also developed several evidence-based criteria for eliminating probable false-positive hotspots (Online Methods and Supplementary Fig. 1b) . In total, we identified 470 statistically significant hotspots (q < 0.01) affecting 275 protein-coding genes (Supplementary Tables 2 and 3) . Overall, more than half of all hotspots were determined to be novel (Fig. 1b, Table 1  and Supplementary Table 2 ) and 54.8% of all tumors assessed here possessed one or more hotspot mutations.
Most affected genes possessed only a single hotspot ( Supplementary  Fig. 3a) . A subset of genes, however, possessed many hotspots of varying frequency. In total, 49 genes possessed two or more hotspots (Fig. 1c) , with many of these also arising in the greatest number of tumor types (Supplementary Fig. 3b ). TP53 R248 was the most disseminated hotspot, observed in 25 tumor types. Among a subset of even well-characterized oncogenes, a pattern of both known and novel hotspots emerged (Fig. 1d) . Moreover, the number of observed mutant amino acids at a given hotspot generally increases with its mutational frequency across tumors types ( Supplementary Fig. 3c ), though 35% (n = 164) of hotspots mutate to only a single variant amino acid. In most genes, hotspots bear only a fraction of the total mutational burden across the gene, whereas in a subset of cancer genes, the dominant mutational hotspot constitutes the vast majority of mutations independent of total mutational burden ( Fig. 1d and Supplementary Fig. 3d ). Overall, we identified considerable variability in the patterns of mRNA expression of individual hotspots in even Fig. 4 ), indicating that levels of expression are often not correlated with the biological importance of known activating mutations.
The patterns by which some hotspots emerge support new clinical paradigms for testing targeted agents. Some hotspots that dominate the mutational landscape in one or a few cancer types also arise as uncommon subsets of many others. For instance, IDH1 R132 is most common in low-grade gliomas, glioblastomas, acute myeloid leukemias (AMLs) and cutaneous melanomas; but it is also present in 1 to 6 tumors in each of 11 additional cancer types. AKT1 E17K arises in greatest numbers in breast cancer, but also in 1 to 3 tumors of 10 additional cancer types. The distribution of CREBBP R1446 mutations is qualitatively different. They were originally identified in relapsed acute lymphoblastic leukemias 17 , but in this cohort of mostly primary disease, we find that they arise in only a small minority (1-3; 0.17-1.7%) of many (11) cancer types. Such patterns reaffirm the value of basket study designs that test mutation-specific inhibitors in early-phase clinical trials, where enrollment is based on specific mutations in patients instead of tissue of origin.
A lineage map of all hotspots in genes with at least one common hotspot ( Fig. 2a and Supplementary Fig. 5 ) indicates most hotspots are defined more by the tissue types rather than the organ systems in which they arise. Of all hotspots, 81% arise in two or more tumor types, suggesting that many hotspot mutations may confer a growth advantage across diverse lineages. Indeed, of hotspots present in multiple tumor types, only 7.6% (n = 36) are confined to a single organ system ( Table 2) . Thus, hotspot mutations that arise in a single tumor type may reflect organ-specific growth advantages, but they represent only a small minority of all hotspot mutations in cancer. Likewise, a subset of hotspots arises in a cell type-specific manner. Twentyseven hotspots (5.7%) were more frequently mutated in tumors of a squamous cell lineage ( Supplementary Fig. 6 ), the most significant of which were MAPK1 E322 and EP300 D1399 (q = 6 × 10 −13 and 1 × 10 −11 , respectively, χ 2 ) and may potentially confer a squamous cell type-specific growth advantage.
Overall, the presence, type and frequency of hotspots by tumor type vary widely (Fig. 2b) . In some tumor types, a large proportion of tumors possess one or more hotspot mutations including a substantial fraction of tumors with a hotspot in a candidate oncogene (Fig. 2b,  top) . Conversely, other tumor types never or rarely possess a tumor defined by a hotspot identified here. Some of these differences are certainly attributable to the fact that hotspots are only one of many possible driver genomic aberrations, including specific gene fusions or focal amplifications and deletions. These other aberrations may define tumors of a given type, but they are not mutually exclusive with hotspots in many cancers. Other differences could not, alone, be explained by the overall mutational burden in these tumor types. For instance, uterine carcinosarcomas and prostate cancers have a similar mutation rate whereas there is a threefold greater frequency of hotspot-bearing tumors among the former. Likewise, whereas papillary thyroid and high-grade pontine gliomas have mutations rates similar to nasopharyngeal tumors and neuroblastomas, the former far more commonly bear hotspot mutations (Fig. 2b) .
Unconventional hotspots
In addition to missense mutations, we identified a variety of unconventional hotspot mutations with varied impact. Among these were 13 splice-site hotspots. For each of these hotspots, an associated transcript abnormality was identified from RNA sequencing of affected tumors (exon skipping, intron retention, in-frame deletions; Supplementary Fig. 7a ), including two previously characterized in-frame activating mutations (MET D1010_splice and PIK3R1 M582_splice, both exon 14 skipping events). We also identified 70 hotspots in 34 genes for which a nonsense mutation was among a a Although previously identified in the germline of patients with associated syndromes and familial cancers, this is the first documentation of somatic mutations.
npg
A n A ly s i s diversity of changes at the affected residue, including 28 hotspots in which only a nonsense mutation was present ( Supplementary  Fig. 7b ). Whereas nonsense mutations scattered throughout a gene may reflect a pattern of loss-of-function consistent with tumorsuppressor activity, a nonsense hotspot would appear to indicate the selection for the selective truncation of specific functional domains. Such events are consistent with the loss of some functions and the retention of others, as has been observed previously in genes such as PIK3R1, NOTCH1 and MET 18, 19 . These hotspots aside, there was a depletion of nonsense mutations in hotspots in constitutively essential genes (P < 10 −16 , those genes predicted or experimentally verified to be essential across all cell and tissue types and developmental states 20 ). Otherwise, the specific impact of nonsense hotspots is generally unknown and belies the disseminated pattern of truncating mutations in likely or proven tumor suppressors (Supplementary Fig. 7c ).
Lineage diversity and mutant allele-specificity The majority of hotspot mutations arose in diverse tumor types and organ systems, yet widespread differences exist among individual residues and mutant amino acids in hotspots, genes and tumor types (Fig. 3a) .
Examining the spectrum of KRAS mutations, which includes the most frequently mutated hotspot overall in our study (KRAS G12; n = 736 mutant tumors; Figs. 1d and 2a), clarified patterns only incidentally observed in the past. We found that gastric cancers were more similar to multiple myeloma in the preponderance of non-G12 mutations compared to endometrial, lung, colorectal and pancreatic tumors (P = 5.3 × 10 −18 ; Supplementary Table 4) . Only colorectal tumors had KRAS A146 mutations, whereas pancreatic tumors lacked G13 mutations (P s = 4 × 10 −7 and 2.8 × 10 −15 , respectively). Many of these lineage-specific patterns were present at finer resolution as well. Among KRAS G12 mutations, the abundance of G12C mutations are highest in lung adenocarcinomas (P = 4 × 10 −42 ), an event that may be associated with prognostic differences compared with non-G12C KRAS mutations [21] [22] [23] . Such mutant amino acid specificity was also apparent in pancreatic tumors, where KRAS G12R was more common than in any other tumor type (21% versus between 0 and 2.6%; χ 2 P = 4.8 × 10 −19 ). Gastric cancers, on the other hand, had the fewest G12V mutations among all KRAS G12-mutant tumor types, but the highest proportion of G12S (P = 0.007, Fig. 3b ).
There is a different balance among hotspots in the other Ras genes. Whereas papillary thyroid cancers nearly exclusively possessed codon Q61 mutations in HRAS and NRAS (P = 4 × 10 −7 ), there was a higher prevalence of G12 and G13 codon mutations in these genes in AMLs, colorectal, bladder, and head and neck cancers, which together share few mutational processes in common (P = 4 × 10 −10 , Fig. 3a) . Similar differences emerged in other driver cancer genes with multiple hotspots. V600E mutations describe nearly all BRAF hotspot mutations in melanoma, papillary thyroid and colorectal carcinomas, whereas multiple myelomas are similar to lung adenocarcinoma in which non-V600E hotspots predominate (P = 1.9 × 10 −32 ). The balance between extracellular and kinase domain mutations in EGFR between brain tumors and lung adenocarcinoma (P = 3.3 × 10 −12 ), respectively, have been documented previously and affect their biological impact and the efficacy of genotype-directed therapy 10 . ERBB2 followed a similar pattern, where extracellular domain mutations typified by S310F are far more common than are kinase domain mutations in bladder cancers compared to breast cancers (P = 0.006, Fig. 3a) . Another notable gene was PIK3CA. Whereas bladder and cervical cancers are similar in their distribution of PIK3CA hotspot mutations, they vary significantly from breast cancers in the overall balance of helical to kinase domain mutations, possessing far fewer H1047  N1044  M1043  Y1021  E726  Q546  E545  E542  E453  C420  C378  N345  V344  G118  K111  G106  R88  E81  R38  R183  P179  D297  V104  M60  L861  L858  G719  G598  A289  R108  Y42  E40  R5  Q61  G13  G12  A146  K117  Q61  GQ60GK  G13  G12  K601  V600  L597  G596  D594  N581  G469 <1  <1  <1  1  <1<1<1  <1<1 <1  1  1  <1  <1<1  <1  <1  <1  <1  <144 7 59 3  1  <1  1  2  1  <1 1  <1  <1  <1  <1  12 Fig. 5 ). (b) The fraction of tumors of a given type (as indicated) affected by one or more hotspots. Black circles represent the median mutation rate (right axis) in the indicated tumor type (bar is the median absolute deviation). Shown at top is the number of tumors of each type with a hotspot mutation affecting a known or candidate oncogene 1 .
npg A n A ly s i s H1047R mutations among PIK3CA-mutated cases (P = 4.8 × 10 −19 ). Endometrial and colorectal cancers also have a similar pattern of PIK3CA hotspots, but both have a higher prevalence of R88Q mutations than any other tumor type (P = 1.3 × 10 −11 ; Fig. 3a) . Such patterns extend beyond essential MAPK or PI3K signaling components, such as with SF3B1 K700 mutations that predominate in breast cancers and chronic lymphocytic leukemias whereas melanomas more frequently possess SF3B1 R625 mutations (P = 0.0001). Finally, mutant amino acid specificity was not limited to hotspots in Ras genes. The IDH1 R132H hotspot mutation predominated in multiple brain tumor types, but cysteine was the most common IDH1 R132 mutant amino acid in melanoma, which is unlikely to be exclusively related to UV light exposure, as this is also true in AMLs that lack a UV-driven etiology (P = 3.9 × 10 −21 ). Together, these results indicate that substantial mutant amino acid specificity exists among hotspot mutations across highly diverse tumor lineages. Two related conclusions may be drawn from these data. First, different hotspots in the same gene may possess in many cases different functions, much of which may be lineage-dependent, while not excluding the possibility that some may still arise as a function of differing underlying mutational mechanisms. Second, that perhaps different mutant amino acids within the same hotspot can be functionally different, support for which idea is growing 8, 11 .
Timing of individual hotspots
We next sought to determine if hotspot mutations, many of which are likely driver mutations and in some cases may serve as the initiating lesion, typically arise earlier than do nonrecurrent mutations in the same genes and are therefore more often clonal. Overall, mutations at hotspot residues more often resided in a greater fraction of tumor cells and therefore arose earlier (presumptive clonal), than non-hotspot mutations in the same genes (Fig. 3c) . So, whereas prior work has shown that driver genes in lung adenocarcinomas were enriched for clonal mutations 24 , we found that this was true of hotspot mutations across a broad class of cancer genes and tumor types. However, there was considerable variability among hotspots. Whereas colorectal and endometrial cancers have a similar pattern of PIK3CA hotspot mutations (Fig. 3a) and share hypermutated subtypes of tumors driven by MSI and POLE exonuclease domain mutations 25, 26 , colorectal tumors were unique in the clonality of the E545 and H1047 mutations. The majority of PIK3CA E545 helical domain mutations in colorectal cancers were subclonal, whereas H1047 kinase domain mutations were clonal, a difference that was not apparent in endometrial tumors, in which both are early clonal mutations (Fig. 3d) . This may be a function of the pattern of oncogenic co-mutation in these tumors as PIK3CA E545, but not H1047, mutations were significantly associated with KRAS mutations in these colorectal cancers (χ 2 P = 0.0004) and in previous cohorts 27 . Overall, these differences in the molecular timing of specific hotspots augurs potentially important differences in their function in tumor initiation versus progression that requires further study.
Population-level hotspots in the long tail
Consistent with the so-called long tail of the frequency distribution of somatically mutated genes across cancer 2 , we found that 85% of all hotspots identified here were mutated in less than 5% of tumors of all cancer types in which they were found (Fig. 4a) . Such findings have led to calls for sequencing up to many thousands of additional specimens from every tumor type 28 . However, many hotspots present at low frequency across cancers are not mutated commonly or significantly in even a single cancer type. Indeed, 23% of all hotspots identified here were present in only one or two samples in the tumor types in which they were observed. This included 19 hotspots arising in only one sample of each affected cancer type such as U2AF1 I24, MYC T58, the hyperactivating MTOR I2500 (ref. 29) , PIK3CB D1067, EP300 H1451 and ERBB3 M60. Conversely, population-level analysis, rather than by individual cancer type or organ system, allows identification of hotspots that arise as even private mutations in rare malignancies, for which additional broad-scale sequencing is most challenging. Although rare, such recurrent alleles are evidence of selection and may be associated with specific phenotypes, such as exceptional responses 30, 31 or de novo resistance to cancer therapy, or may reveal specific facets of pathway biology. Consequently, we found that notable long-tail hotspots affect a broad spectrum of abnormal molecular function including macromolecular transport and transcriptional regulation ( Table 1 , Supplementary Note and Supplementary Fig. 8 ), as well as essential components of key signaling pathways.
Long-tail hotspots in Ras superfamily members
Mutations in the Ras family of small GTPases occur widely in human cancers. As expected, these were among the most significant hotspots detected here (Supplementary Table 2) , affecting 1,335 tumors (12% of all cases). Whereas G12, G13 and Q61 codon hotspots predominate in KRAS, NRAS and HRAS, albeit at varying frequencies in different tumor types (Figs. 2a and 3a) , we also identified GQ60GK, K117 and A146 hotspots in KRAS. Both K117 and A146 are known activating hotspots in the long tail, but we also identified a previously occult GQ60GK dinucleotide substitution (q = 2.3 × 10 −6 ) in 11 tumors. This dinucleotide substitution results in a Q61K mutation accompanied by a G60 synonymous mutation that are present in cis (2) Shown are the ten most significant hotspots that arise in multiple tumor types of a single organ system. a Number in parentheses is the count of affected tumors of the indicated cancer type. b q-value is estimated from P-values produced by the binomial model described in Online Methods. npg A n A ly s i s (in concomitant RNA sequencing; Supplementary Fig. 9 ). Although Q > K mutations at codon 61 can result from 3′ G > T single-nucleotide mutations in KRAS, 100% of these tumors harbored the dinucleotide substitution, a rare spontaneous event in human genomes. Overall, the distribution of codon 61 mutations in KRAS, NRAS and HRAS are very different, with Q > K mutations occurring significantly less frequently in KRAS (P = 0.016; Fig. 4b) . GA > TT mutations were the most common dinucleotide substitution producing GQ60GK (Fig. 4c) and converts the ACC codon at KRAS G60 to TCC, which is the sequence of the G60 codon in NRAS, in which Q61K mutations are far more common and arise nearly exclusively from single-nucleotide mutations. It remains to be determined whether KRAS GQ60GK is therefore driven by a pattern of codon usage at the −1 position. Notably, only one tumor had evidence of a non-KRAS GQ60GK mutation, an NRAS-mutant cutaneous melanoma (Fig. 4c  and Supplementary Table 5) .
We next explored whether KRAS GQ60GK may serve as a driver of Ras pathway activity as do conventional KRAS hotspots. GQ60GK is indeed present in diverse tumor types that all have well-established Ras-driven subsets (Supplementary Table 5 ). Reasoning that if GQ60GK were a passenger mutation in Ras-driven tumors, alternative MAPK-activating mutations may be present in these tumors. Instead, we found that in every GQ60GK-mutant sample where another putative driver of MAPK signaling was present, that lesion was either (i) subclonal, defining a different clone than did GQ60GK; (ii) low activity; or (iii) a passenger mutation (Supplementary Table 5) . Also, despite the frequency of GA > TT, there was no evidence that a common underlying mutational process or exogenous mutagen was the source of GQ60GK. There was no evidence of UV light exposure in the clinical histories or nucleotide contexts of most affected cases, only one of which was a cutaneous melanoma. Moreover, GQ60GK arose in both hypermutated (MSI-H colon lacking BRAF V600E) and nonhypermutated tumors. Finally, rare G60 missense mutations were evident in KRAS and HRAS in this data set and in the literature (Supplementary Table 5) (ref. 32) . So, although we cannot exclude the possibility that the GQ60GK dinucleotide substitution is Uterine (49) Multiple myeloma (40) Gastric (30) G12 (688) G13 (86) G60 (6) Q61 (63) K117 (6) A146 (26)
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A n A ly s i s simply an alternative mechanism to achieve Q61K, the accompanying KRAS-specific G60 synonymous mutation may potentiate a different class of Q61-mutant tumors or cause signaling differences among Q61K-mutant tumors between KRAS, NRAS or HRAS. Although further studies will need to explore the molecular properties of KRAS GQ60GK, this allele represents the most common dinucleotide substitution spanning two codons in human cancer and a mutation more common than other known hotspots in KRAS.
Novel long-tail hotspots were also identified in two other genes that encode members of the Ras superfamily of small GTPases. RAC1, in which we identified two hotspots, is a Rho subfamily member that plays a vital role in various cellular functions. RAC1 P29S is an oncogenic hotspot in melanomas 12, 33 , that we also identified in head and neck, and endometrial cancers (Fig. 4d) . This mutation can confer resistance to RAF inhibitor treatment in vitro 34 , and may underlie early resistance in patients 35 . We also identified a novel RAC1 A159V hotspot present in 10 tumors (q = 2.27 × 10 −6 ; Fig. 4d) . Notably, RAC1 A159V is paralogous to KRAS A146, a known activating mutation 36 . Whereas activating KRAS A146T mutations arise predominantly in colorectal carcinomas (Supplementary Table 2) , RAC1 A159V mutations are most common in head and neck cancers and were not present in any melanomas, despite the frequency of RAC1 P29S in this cancer type. Moreover, similar to P29S mutations, we observed RAC1 A159V mutations in tumors that are both Ras/Raf wild-type and mutant (Fig. 4e) . To determine whether RAC1 A159V is an activating mutation, we assessed its effect in vitro. Active RAC1 is GTP-bound, interacting with PAK1 to activate downstream effectors. Therefore, to quantify RAC1 activation in vitro, we used a PAK1 pull-down assay. In HEK293T cells expressing RAC1 A159V, there was substantial RAC1 activation to levels equal to or exceeding positive-control RAC1 GTPγS cells and greater than even those levels induced by the known RAC1 P29S oncogenic mutation (Fig. 4f) . Moreover, cells expressing RAC1 Q61R, a mutation we identified in a primary prostate cancer that is paralogous to KRAS Q61, also potently induced RAC1 activation (Fig. 4d,f) .
RRAS2 is a Ras-related small GTPase 37 . RRAS2 is overexpressed or mutated in a small number of cancer cell lines of various origins [38] [39] [40] , and is oncogenic in vitro with transforming ability similar to that of established Ras oncoproteins 41 . However, it has not been documented as somatically mutated in human tumor specimens. Here, we identified a RRAS2 Q72 hotspot present in nine tumors (q = 8 × 10 −15 ). 
A n A ly s i s
Similar to RAC1 A159V, the RRAS2 Q72 hotspot is paralogous to KRAS Q61 (Fig. 4d) . However, unlike RAC1, RRAS2 Q72 does not predominate in any individual tumor type. Also unlike RAC1, the RRAS2 Q72 mutation was present in Ras/Raf wild-type tumors among the affected types (Fig. 4e) . This result suggests that RRAS2 activation may be an alternative avenue for tumors to acquire Ras-like activation as previous studies have shown that RRAS2 shares many Ras downstream signaling elements including phosphatidylinositol-3 kinase (PI3K) 42, 43 , the Ral GDP dissociation pathway 42 , and Raf kinases 44 . Beyond these hotspots, several less common RAC1 and RRAS2 mutations affect paralogous residues of highly recurrent alleles in KRAS (Fig. 4d) ; some which we validated were also activating in vitro (Fig. 4f) , indicating that the landscape of potentially functional mutations in these genes extends beyond even these less common long-tail hotspots to private mutations as well.
DISCUSSION
Although we focused only on recurrent substitutions, we did find that whereas a subset of hotspots were prevalent in individual cancer types, most hotspots were present infrequently across many cancer types. This indicates that studies of any individual cancer type may have limited power to identify novel alleles. We have also begun to detail best practices for the use of diverse public cancer sequencing data in the translational setting. Our approach for hotspot detection incorporates features such as the variable background mutational burden of individual codons and genes, thereby avoiding passenger mutations whose recurrence is due only to their presence in highly mutable amino acids. Although the identification of private driver mutations remains challenging, our approach did uncover low-incidence hotspots in highly mutated genes. Though less common, these hotspots are under selection and may confer important clinical phenotypes in cancer patients, such as exceptional responses to cancer therapy 30, 31 .
New mutant alleles in established genes are likely to emerge faster than new cancer genes are identified, extending the long tail of the frequency distribution of somatic mutations. This is especially true as clinical sequencing focuses on profiling advanced and metastatic disease for clinical trial enrollment. Such pretreated, late-stage cases have been historically under-represented among such populationscale resources, including the one studied here. Moreover, at present there are fewer actionable mutations in cancer than there are cancer genes. Yet the near-term clinical utility of expanding the former is far greater than adding to the latter. Our results suggest this will require an understanding of the function of different hotspot mutants in the same gene by lineage, as their function and response to therapy may be specific to the mutant amino acid. Although positive selective pressure may produce the same hotspot mutation, or different variant amino acid changes within the same hotspot residue, it does not imply that they will confer similar selective advantages across lineages. Underlying functional distinctions may explain the differences observed here in the emergence and frequencies of hotspots across lineages. Although this remains speculative or unknown for most hotspots, early evidence suggests that this will be true for even some of the most important alleles in human cancer 8, 9, 11 . Understanding this landscape of distinct molecular function is the necessary translational prerequisite for effective clinical implementation. This focus on mutations rather than genes will spur studies of the biochemical, biological, signaling impact and drug sensitivity of candidate individual alleles. Collectively, the complementary study of both significantly mutated individual alleles as well as genes will prove indispensable in enabling precision oncology through clinical decision support for patients sequenced at the point of care.
METHODS
Methods and any associated references are available in the online version of the paper. 
